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University, Ames, IowaABSTRACT In Alzheimer’s disease, cytochrome c-dependent apoptosis is a crucial pathway in neuronal cell death. Although
beta-amyloid (Ab) oligomers are known to be the neurotoxins responsible for neuronal cell death, the underlying mechanisms
remain largely elusive. Here, we report that the oligomeric form of synthetic Ab of 42 amino acids elicits death of HT-22 cells. But,
when expression of a bcl-2 family protein BAK is suppressed by siRNA, Ab oligomer-induced cell death was reduced. Further-
more, significant reduction of cytochrome c release was observed with mitochondria isolated from BAK siRNA-treated HT-22
cells. Our in vitro experiments demonstrate that Ab oligomers bind to BAK on the membrane and induce apoptotic BAK pores
and cytochrome c release. Thus, the results suggest that Ab oligomers function as apoptotic ligands and hijack the intrinsic
apoptotic pathway to cause unintended neuronal cell death.INTRODUCTIONAlzheimer’s disease (AD), a progressive neurodegenerative
disorder, may be identified by the accumulation of senile
plaques, neurofibrillary tangles, and substantial loss of brain
mass (1,2). Mounting evidence clearly indicates that intra-
cellular beta-amyloid (Ab) oligomers are the neurotoxins
responsible for neuronal cell death in AD (3–7). Neuronal
cell death, commonly found among AD patients and patho-
logically significant due to its irreversibility, may be a result
of apoptosis, specifically the release of cytochrome c from
the mitochondria (8,9). Cytochrome c release, which is a
pivotal step in apoptosis, triggers a cascade of caspase
activation that leads to cell death. Under normal apoptotic
conditions, cytochrome c is thought to be released through
apoptotic pores in the mitochondrial outer membrane
(MOM), which are induced by the activation of BAK or
BAX via caspase-8-cleaved BID (tBID, p15 BID) (10–12).
The notion that Ab oligomers induce neuronal cell death
via apoptosis in AD is based on apoptotic markers found in
postmortem AD brain such as DNA fragmentations,
increased bcl-2 family protein expression, increased caspase
activities (13,14), and cell-level studies that show elevated
levels of cytochrome c found in the cytosol (12,15). More-
over, some studies demonstrate that Ab oligomers elicit
cytochrome c release from isolated mitochondria (16,17).
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0006-3495/14/10/1601/8 $2.00Ab localize to the mitochondria and lead to mitochondrial
dysfunction by interacting with mitochondrial proteins, by
blocking mitochondrial import channels, by disrupting elec-
tron-transport chain, or by increasing reactive-oxygen spe-
cies products (18,19). However, these mitochondrial
dysfunctions do not satisfactorily explain the Ab-induced
cytochrome c release.
In this work, we investigate the direct involvement of a
bcl-2 family protein BAK in Ab-induced cytochrome c
release and neuronal cell death. In cells, suppression of
BAK expression with siRNA resulted in reduced cell death
by Ab oligomers. Isolated mitochondria from siRNA-
treated cells showed decreased release of cytochrome c by
Ab oligomers, together linking BAK to Ab oligomer-
induced cytochrome c release and cell death. Further on,
in a well-defined in vitro setting, we unambiguously show
that Ab oligomers interact with BAK and trigger the release
of cytochrome c from MOM-like vesicles. The results raise
the possibility that Ab oligomers hijack the cytochrome
c-dependent apoptotic pathway by interacting with BAK
even in the absence of the death signal, leading to cell death.MATERIALS AND METHODS
Preparation of Ab oligomers
The synthetic peptide wild-type Ab (1–42) was purchased from American
Peptide (Sunnyvale, CA). As described in Dahlgren et al. (20) and Ahmed
et al. (21), the Ab (1–42) peptide was initially dissolved to 1 mM in hexa-
fluoroisopropanol (Sigma-Aldrich, St. Louis, MO) and separated into
aliquots in sterile microcentrifuge tubes. Hexafluoroisopropanol was
removed under vacuum in a SpeedVac (Thermo Fisher Scientific, Rockford,http://dx.doi.org/10.1016/j.bpj.2014.07.074
1602 Kim et al.lL) and the peptide film was stored desiccated at 80C. To make oligo-
mers, cold phosphate-buffered saline was added to bring the peptide to a
final concentration of 10 mM and incubated at 4C for 18 h (see Fig. S1
in the Supporting Material).Expression and purification of
recombinant proteins
The mouse BAK protein containing amino acids 16–184 (BAKDC) was
prepared with a C-terminal histidine (6) tag using pPosKJ-sBAK-cHis
plasmid as described in Oh et al. (22). N-terminal His6-tagged Bid (p22
BID) was purified, and p7/p15 BID or cBID, an activated form of BID,
was prepared from the p22BID protein after cleavage with caspase-8, as
described in Oh et al. (23). The fragment p22BID forms a tight complex
as p7/p15 BID (cBID). All protein preparations were stored in 18% glyc-
erol, 20 mM Tris buffer (pH 7.4), and 150 mM KCl at 80C. The protein
concentration was determined using the bicinchoninic acid protein assay kit
(Thermo Fisher Scientific), and purified proteins were examined with 15%
sodium dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE),
and the purity was at least 95% for all proteins (see Fig. S3 B).Cell culture and gene silencing
HT-22 cells were cultured in Dulbecco’s modified Eagle’s medium (Invitro-
gen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine
serum, 1% penicillin/streptomycin at 37C in a 5% CO2 incubator. After
24 h incubation, BAK siRNA transfection was performed with an siRNA
transfection reagent (Santa Cruz Biotechnology, Dallas, TX) according to
the manufacturer’s instructions. Briefly, transfection reagent and BAK
siRNA or nonfunctional control siRNAwere dissolved separately in a dilu-
tion buffer and the respective transfection mixtures were added to the anti-
biotic and serum-free cell culture medium to a final concentration of 20 nM
siRNA. Six hours after transfections, the 2 medium (DMEM with 20%
FBS and 2% antibiotics) was added to the siRNA-treated HT22 cells, and
the cells were further incubated for 18 h.Mitochondria isolation and cytochrome c release
assay
Mitochondria were isolated using a Mitochondrial Isolation Kit for
Cultured Cells (Thermo Fisher Scientific) according to the manufacturer’s
instructions. Isolated mitochondria were incubated with the indicated con-
centrations of cBID and Ab oligomers for 45 min at room temperature in
mitochondria buffer (150 mM KCl, 5 mM MgCl2, 1 mM EGTA, 25 mM
HEPES, 1 mM DTT pH 7.5) under constant stirring using a Thermomixer
(Vfinal ¼ 100 mL; Eppendorf, Hamburg, Germany). Reaction mixtures were
centrifuged at 14,000 g for 15 min, with cytochrome c quantitated using a
colorimetric ELISA (Invitrogen) according to the manufacturer’s protocol.
Briefly, supernatant fraction was added to the well of a microtiter plate pre-
coated with monoclonal anti-cytochrome c antibody, followed by adding
100 mL of cytochrome c biotin conjugate solution for 1 h at room temper-
ature (RT). Then, 100 mL of streptavidin-HRP working solution was added
for 30 min at RT. After adding 100 mL of stabilized chromogen, equal
volume of stop solution was also added and the product was measured on
a spectrophotometer at 450 nm.Immunoblotting
For Western blot analysis, HT-22 cells were lysed with RIPA buffer (Cell
Signaling Technology, Danvers, MA) with Protease Inhibitor Cocktail
(Calbiochem, Darmstadt, Germany). After centrifugation at 15,000  g
for 15 min at 4C, total protein amounts were determined with the BCABiophysical Journal 107(7) 1601–1608Protein Assay kit (Bio-Rad, Hercules, CA). Equal amounts of protein ly-
sates were separated by SDS-PAGE electrophoresis, and transferred to
nitrocellulose membrane. The blot was probed with an anti-BAK rabbit
polyclonal antibody (G-23) at 4C overnight. Membranes were then
exposed to the HRP-conjugated rabbit anti-goat secondary antibody
(Sigma-Aldrich) followed by a chemiluminescence detection of antibody
binding (Thermo Fisher Scientific). Equal protein loading was controlled
by reprobing the membrane with a monoclonal anti-b-actin antibody
(Sigma-Aldrich).Cofloatation assay
To measure the binding properties of Ab oligomers to proteoliposomes (li-
posomes reconstituted with BAKDC only or BAKDC/cBID or cBID only),
each vesicle (100 mM) was incubated with Ab oligomers for 30 min at room
temperature, then air-fused at high speed (Airfuse; Beckman Instruments,
Brea, CA). The amounts of bound Ab oligomers were measured by Dot
blot using anti-amyloid oligomer antibody (A11; Millipore, Billerica,
MA). The proteins bound on the liposomes were detected by Western
blot using the BAK (G-23) or BID (FL-195) antibodies purchased from
Santa Cruz Biotechnology.Cytochrome c labeling and MOM-like vesicle
preparation
For dye labeling, cytochrome c (from equine heart, Sigma-Aldrich) in phos-
phate-buffered saline (137 mM NaCl, 10.13 mM Na2HPO4, 2.68 mM KCl,
1.76 mM KH2PO4, pH 7.4) was incubated with twofold excess of Cy3 suc-
cinimide ester (Lumiprobe, Hallandale Beach, FL) for 6 h at 4C, such that
~1–2 Cy3 dyes were labeled per cytochrome c. Free dyes were removed
from the solution by using the PD-10 desalting column (GE Healthcare, Pis-
cataway, NJ).
Lipids were purchased from Avanti Polar Lipids (Alabaster, AL). Lipids in
organic solvent were mixed, in accordance with previous work (22,24), with
the molar ratio 36:21.9:9:8:20:5 for POPC (1-palmitoyl-2-oleoyl-sn-glycero-
3-phosphocholine)/POPE (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoe-
thanolamine)/POPS (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoserine)/
cholesterol/cardiolipin (from beef heart)/DOGS-NTA-Ni (nickel salt; 1,2-
dioleoyl-sn-glycero-3-([N-5-amino-1-carboxylpentyl)-iminodiacetic acid]
succinyl).
For the surface-attachment, 0.1 mol % of biotin-DPPE (1,2-dipalmitoyl-
sn-glycero-3-phosphoethanolamine-N-(cap biotinyl)) lipid was added to
the lipid solution. The lipid mixture was completely dried using the nitro-
gen gas and further dried with a vacuum pump for at least 3 h. The dried
lipid film was resuspended in ~15 mM Cy3-labeled cytochrome c. After
five freeze/thaw cycles, large unilamellar vesicles (~200 nm diameter)
were prepared by extrusion through polycarbonate filters (Avanti Polar
Lipids) (see Fig. S3 C). Untrapped cytochrome c was removed by air-fused
centrifugation (Airfuse; Beckman Instruments).Single-vesicle cytochrome c release assay
The flow chambers were assembled on a quartz imaging surface function-
alized with PEG (polyethylene glycol) and PEG-biotin molecules (molar
ratio 40:1; Laysan Bio, Arab, AL) followed by streptavidin (0.2 mg/mL,
Sigma-Aldrich) incubation for 10 min. After washing several times, the
MOM-like vesicles are injected into the chamber and immobilized, fol-
lowed by the washing of free vesicles with 500 mL injection of buffer
(50 mM Tris-HCl, pH7.4, 150 mM KCl). Once immobilized, photobleach-
ing safe laser intensity is secured, then BAKDC, cBID, and other proteins
are injected into the flow chamber. The vesicles were monitored with a
prism-type total internal reflection fluorescence (TIRF) microscope
attached to an electron-multiplying charge-coupled device camera for dig-
ital image processing (see Fig. S4 A).
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Photobleaching is induced by the destruction of fluorophores via light ex-
posure that results in a decrease in fluorescence emission. A laser intensity
that does not alter the fluorescence intensity of the MOM-like vesicle for a
10- or 20-min observation period must be secured. We used the first flow
chamber (out of a total of 10) in every slide to calibrate the maximum laser
intensity that does not induce photobleaching (see Fig. S4 B). All experi-
ments within the respective slide were carried out below the photobleaching
safe intensity.TIRF data processing
The image streaming of the sample chamber from the electron-multiplying
charge-coupled device camera connected to the TIRF microscope was
collected using single molecule software developed by Dr. Jong-Bong
Lee at POSTECH (Pohang University of Science and Technology, Pohang,
South Korea). The time traces of the fluorescence intensity of the MOM-
like vesicles were then extracted using interactive data language. Once
the time traces for the vesicles were obtained, preliminary categorizations
of the fluorescence intensity, specifically detection of stepwise drops that
correspond to cytochrome c release, were performed using a step-detection
program (25). The categorized data were then manually examined one by
one to exclude any false-positives.Purification of a-synuclein and preparation of
large a-synuclein oligomers
Recombinant GST-fused a-synuclein was expressed in Escherichia coliRo-
setta (DE3) pLysS (Novagen, Darmstadt, Germany). The cells were grown
at 37C in LB medium with 100 mg/mL ampicillin until the absorbance at
600 nm reached 0.6–0.8. Isopropyl b-D-1-thiogalactopyranoside (0.5 mM
final concentration) was then added to induce protein expression. Cells
were grown for another 12 h at 16C. GST fusion protein was purified
with affinity chromatography using glutathione-agarose beads and then
cleaved off from the resin by incubating with thrombin at room temperature
for 2 h. To prepare large a-synuclein oligomers, 10 mM of a-synuclein was
mixed with 100 mM dopamine in 20 mM sodium phosphate buffer (pH 7) at
37C for 72 h. After incubation, the mixture was centrifuged to remove
large aggregates at 13,000  g for 5 min at 4C. Then, the supernatant
was concentrated using Ultracel 10 K membrane (Millipore). Large oligo-
mers were purified by size exclusion chromatography using Superdex
200 10/300 GL (GE Healthcare) and concentrated again using Ultracel
10 K-membrane (26).FIGURE 1 Ab oligomer-induced cell death and cytochrome c release
from siRNA-transfected and normal HT-22 cells. (A) Cell viability of
HT-22 cells was evaluated with the MTT assay, 12 h and 24 h, after treat-
ment of the indicated concentrations of Ab oligomers. Transfected Ab olig-
omers were confirmed with Dot blot using anti-b amyloid (6E10) antibody.
The data represent the mean 5 SD of three independent experiments. (B)
Immunoblot analysis of BAK and Ab oligomers protein in HT-22 cells
using anti-BAK and anti-b amyloid (6E10) antibody. HT-22 cells were pre-Dynamic light scattering (DLS)
The size distribution of MOM-like vesicles and Ab oligomers were
analyzed by DLS with Zetasizer nano Zs (Malvern Instruments, Malvern,
Worcestershire, UK) at a fixed angle of 173 at 25C. The MOM-like ves-
icles (10 mM lipid concentration) were subjected to the DLS measurement
after 10-min centrifugation at 13,000 rpm. The data was analyzed by the cu-
mulative method using software provided by the instrument.treated with/without the 20 nMBAK siRNA for18 h. A quantity of 1000 nM
Ab oligomers were treated with protein transfection regents. Anti-b-actin
and anti-Bid antibodies used as control is shown. (C) Ab oligomer-induced
cell death was compared in normal and BAK KD HT-22 cells using the
MTTassay. The data represent the mean5 SD of three independent exper-
iments (*** P < 0.005; ** P < 0.01 compared with Ab oligomers-treated
(1 mM) normal HT-22 cells pretreated with vehicle). (D) Measurement of
cytochrome c release from isolated mitochondria of HT-22 cells using a
colorimetric ELISA assay kit (Invitrogen). The data represent the
mean 5 SD of four independent experiments. Concentrations are given
in moles of monomeric Ab. To see this figure in color, go online.RESULTS
BAK is involved in cytochrome c release by Ab
oligomers
We prepared synthetic 42-amino-acid-long Ab peptide and
converted it to oligomers by incubation at 4C for 16 h
(21). The DLS analysis of Ab oligomers shows a single
peak at ~17 nm (see Fig. S1 A), which is in coherencewith previous studies that report 10~20-nm-sized Ab oligo-
mers are pentamers/hexamers (21,27). We tested the toxicity
of our synthetic Ab oligomers on HT-22 cells with the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) assay. We delivered Ab oligomers directly
into the cytoplasm of HT-22 cells using the protein transfec-
tion method and measured cell viability (Fig. 1 A). Although
Ab oligomers did not harm cell viability at concentrations
up to 1000 nM (see Fig. S2) in the period of first 3 h, exog-
enous Ab oligomers induce cell death at longer exposure
times (Fig. 1 A) (28).
To address the potential role of BAK in Ab oligo-
mers-induced cell death, we took a gene-silencing approach
using BAK siRNA that reduced BAK mRNA and con-
sequently, protein levels (Fig. 1 B). We observed that AbBiophysical Journal 107(7) 1601–1608
1604 Kim et al.oligomer-induced cell death in BAK knockdown (KD)
HT-22 cells was significantly reduced when compared to un-
treated HT-22 cells (Fig. 1 C), strongly suggesting that Ab
oligomers may play a role in the BAK-dependent apoptotic
pathway.
To narrow down the potential targets of Ab oligomers, we
extracted the mitochondria from both normal and BAK KD
HT-22 cells and compared the amount of cytochrome c
release induced by Ab oligomers with the ELISA assay
(28,29). Remarkably, for mitochondria from BAK KD HT-
22 cells, a significant reduction in cytochrome c release
was observed when compared with that from normal cells
(Fig. 1 D). Thus, our results show that Ab oligomers most
likely target BAK for cytochrome c release.
As controls, we induced the cytochrome c release from
isolated mitochondria with cBID (p7/p15 BID), which is a
potent apoptotic trigger for both BAK and BAX.As expected,Biophysical Journal 107(7) 1601–1608we observed a cBID-concentration-dependent increase in
cytochrome c release, suggesting that cytochrome c release
machinery works normally in isolated mitochondria. Further-
more, significantly less cytochrome c release out of mito-
chondria extracted from BAK KD HT-22 cells than that
from a normal cell at 500 nM cBID is consistent with reduced
BAK protein levels in the siRNA-treated cells.Single-vesicle cytochrome c release assay
To investigate the effects of Ab oligomers on apoptotic
BAK pores without involving other mitochondrial protein
factors, we developed a well-defined in vitro single-vesicle
assay that can monitor the real-time dynamics of cyto-
chrome c release from single MOM-like vesicles (Fig.
2 A). MOM-like vesicles were encapsulated with Cy3-
labeled cytochrome c and immobilized on the quartzFIGURE 2 In vitro single-vesicle cytochrome c
release assay. (A) Experimental design of the sin-
gle-vesicle cytochrome c release assay system.
The initial state starts with Cy3-labeled cyto-
chrome c encapsulated MOM-like vesicles tethered
to a PEG-coated quartz surface via biotin-streptavi-
din interactions (red arrow). Then BAKDC and
cBID are injected into the flow chamber, inducing
apoptotic BAK pores followed by cytochrome c
release. (Inset, below) Soluble form of recombinant
mouse BAK protein (BAKDC, residues 16–184)
with a C-terminal hexa-histidine tag (see Fig. S3
A in the Supporting Material) tethered onto an Ni-
NTA lipid. (B) Representative time traces of Cy3-
labeled cytochrome c release via apoptotic BAK
pore formation. (C) The cumulative histogram of
cytochrome c release when treated with the indi-
cated concentrations of recombinant apoptotic pro-
teins observed for 10 min (100-ms time binning).
(D) Total cytochrome c release histogram of the
indicated concentrations of recombinant apoptotic
proteins after 10 min. Data in panels C and D rep-
resents the mean5 SD of five independent exper-
iments. To see this figure in color, go online.
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scope. Next, a mixture of recombinant BAK without the
transmembrane helix (BAKDC) and cBID is injected into
the flow chamber. BAKDC is a recombinant form of BAK
that has been frequently used for the structural and func-
tional investigations of BAK (22,24,30,31). Hexa-histidine
tag on the C-terminal end of BAKDC tethers onto the Ni-
NTA lipid, mimicking its membrane anchor (Fig. 2 A, inset
below; and see Fig. S3 A). When BAKDC is activated by
cBID, we observed the release of Cy3-labeled cytochrome
c, which resulted in a sudden drop in the fluorescence inten-
sity (Fig. 2 B). Intensity drop due to release differs from
slow intensity decline due to photobleaching (see Fig. S4 B).
As expected, we observed an increase in cytochrome c
release events as BAKDC and cBID concentrations were
increased. Specifically, after a 10-min observation period,
~11% of the surface-immobilized vesicles exhibited cyto-
chrome c release at 40 nM for both BAKDC and cBID
(Fig. 2, C and D). Cytochrome c release was not observed
in the absence of either BAKDC or cBID (see Table S1 in
the Supporting Material), consistent with the results from
previous in vitro experiments (22,30). The necessity of
both BAKDC and cBID was also confirmed by using sulfo-
rhodamine (SRB)-dextran fluorescent dyes in our in vitro
single-vesicle assay (see Table S2). Thus, the results vali-
date our assay for the study of apoptotic BAK pores and
cytochrome c release (30,32–34).Ab oligomers induce formation of apoptotic
BAK pores
Here, we take an in vitro approach to investigate whether Ab
oligomers and BAK alone can induce cytochrome c release.
Because some studies relate Ab oligomers with direct MOM
permeabilization (15,35,36), we tested whether Ab oligo-
mers could independently induce cytochrome c release
from protein-free MOM-like vesicles. High concentration
(1 mM, in monomer concentration) injections of Ab oligo-
mers, into the flow, in the absence of BAKDC did not exhibit
any fluorescence intensity change (see Table S3), assuring
that at concentrations lower than 1 mM, Ab oligomers alone
could not induce protein pores or membrane permeability
that would enable cytochrome c release.
When Ab oligomers and BAKDC were injected into the
flow chamber, cytochrome c release is clearly observed
from the vesicles (Fig. 3 A and see Table S4). Specifically,
~12% of the vesicles displayed cytochrome c release, after
10 min, when treated with 200 nM Ab oligomers (in mono-
mer concentration) and 40 nM BAKDC.
Our in vitro single-vesicle results suggest that Ab oligo-
mers directly induce apoptotic BAK pores and thus, it is
highly likely that there is a physical interaction between
Ab oligomers and BAK. To test this hypothesis, we per-
formed a modified cofloatation assay in a cell-free mem-
brane environment. Ab oligomers were incubated withBAKDC, cBID, or BAKDC/cBID proteoliposomes, respec-
tively. Vesicles were collected from the pellets after centri-
fugation, then separated by SDS-PAGE and transferred onto
Western blot.
The results show that Ab oligomers bind strongly with
BAKDC and BAKDC/cBID proteoliposomes. However, a
weak interaction is also observed between Ab oligomers
and cBID proteoliposomes. The weak intensity of Ab oligo-
mers binding to cBID appears to represent nonspecific Ab
oligomers binding to the lipid bilayer as opposed to direct
binding with cBID, because a comparable intensity was
also observed in the mixture of Ab oligomers and protein-
free liposome. Consistently, the supernatant fractions contain
a high concentration of unbound Ab oligomers when incu-
bated with cBID, whereas significantly fewer free Ab oligo-
mers were present when incubated with BAKDC (Fig. 3 B).
Therefore, our results confirm that Ab oligomers indeed
directly bindwithBAKDC tethered on theMOM-likevesicle.Ab oligomers accelerate BAK/cBID mediated
apoptotic pores
We have identified that cBID and Ab oligomers induce
apoptotic BAK pores mutually independently. Now, we
investigated whether the two can work synergistically. Exper-
iments were performed with various concentrations of Ab
oligomers whereas BAKDC and cBID concentrations were
fixed at 40 nM. Although it is not obvious at low concentra-
tions of Ab oligomers, the results clearly show that cBID and
Ab oligomers are synergic in enhancing cytochrome c
release at 200 nM (Fig. 3 C). There is a twofold increase
compared to the linear sum of those when cBID and Ab olig-
omers are individually present (Fig. 3 D). The results raise
the possibility that Ab oligomers have the capacity to accel-
erate cBID-induced apoptotic BAK pore formation, in addi-
tion to its ability to induce BAK pore formation on their own.Do a-synuclein, tau induce apoptotic BAK pores?
Next, we investigated the specificity of Ab oligomers by
testing the effects of other well-known dementia-inducing
proteins (DIPs) on apoptotic BAK pore formation (1,5,37).
We first tested whether the various forms, either monomer
or oligomers, of tau, a-synuclein, or Ab (1 mM) could inde-
pendently release cytochrome c from the vesicles without
BAKDC. After 10 min, cytochrome c release did not occur
in all cases (see Table S3), providing grounds that the DIPs
alone do not puncture the vesicles. Next, we injected
BAKDC with DIPs. Our results clearly show that only Ab
oligomers possess the ability to induce apoptotic BAK
pores (Fig. 4 A). In addition, we also investigated the pro/
anti-apoptotic effects of DIPs on cBID-induced apoptotic
BAK pores. Except for Ab oligomers, other DIPs did not
cause any alterations in the cytochrome c release rates
(Fig. 4 B). Thus, the results show that Ab oligomersBiophysical Journal 107(7) 1601–1608
FIGURE 3 Cytochrome c release via Ab
oligomer-induced apoptotic BAK pores. (A) The
cumulative histogram of cytochrome c release
when treated with the indicated concentrations of
Ab oligomers and 40 nM BAKDC observed for
10 min. The data represent the mean 5 SD of
five independent experiments. (B) Cofloatation
assay of Ab oligomers interaction with proteolipo-
somes. Liposomes treated with BAKDC and/or
cBID mixed with/without Ab oligomers, and
precipitated with high-speed centrifugation. The
amount of vesicle-bound Ab oligomer was quanti-
fied by Dot blot. The data represent the mean 5
SD of three independent experiments. The quanti-
fication of the bound levels of Ab oligomers
(red box) was performed with the software
QUANTITY ONE (Bio-Rad). (C) The cumulative
histogram of cytochrome c release when treated
with the indicated concentrations of Ab oligomers
40 nM BAKDC and 40 nM cBID, observed for
10 min. (D) Total cytochrome c release histogram
of the indicated concentrations of Ab oligomers
40 nM BAKDC and 40 nM cBID, compared to
the sum of 40 nM BAKDC, 40 nM cBID, 40 nM
BAKDC Ab oligomers (indicated concentration)
after 10 min. Data in panels C and D represent
the mean5 SD of five independent experiments.
Concentrations are given in moles of monomeric
Ab. To see this figure in color, go online.
1606 Kim et al.specifically induce apoptotic pores and accelerate the for-
mation of cBID-induced apoptotic BAK pores.DISCUSSION
Studies implicate that Ab oligomers are the key modulators
of cytochrome c release in relation to neuronal cell death in
AD. Ab is known to be produced by enzymatic cleavage of
amyloid precursor protein, located on the plasma mem-
brane, and normally excreted to the extracellular spaceBiophysical Journal 107(7) 1601–1608(1,2,38). However, some studies show that Ab is often
cleaved prematurely from the ER and Golgi and is also traf-
ficked back into the cytosol in the significant numbers
sufficient to cause physiological difficulties (7,39,40).
Cell-level studies link Ab oligomers with elevation of reac-
tive oxygen species, transition in the MOM permeability,
mitochondrial morphological change, and alteration of
the expression level of various bcl-2 family proteins
(15,18,19,28). It is clear that intracellular Ab oligomers
target the mitochondria and exhibit neurotoxic effects.FIGURE 4 The effect of DIPs on apoptotic
BAK pores. The cumulative histogram of cyto-
chrome c release when treated with the indicated
DIPs (200 nM) along with (A) 40 nM BAKDC
or (B) 40 nM BAKDC and 40 nM cBID observed
for 10 min. Data represent the mean 5 SD of
five independent experiments. Concentrations are
given in moles of monomeric Ab, tau, and a-syn-
uclein. To see this figure in color, go online.
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mers induce cytochrome c release is yet to be elucidated.
Here we show that Ab oligomers physically target BAK
and hijack the intrinsic apoptotic pathway (Fig. 5).
We observed significantly reduced Ab oligomer-induced
cell death in BAK KD HT-22 cells. Moreover, Ab olig-
omer-induced cytochrome c release out of isolated mito-
chondria from BAK KD HT-22 cells was reduced when
compared with that from mitochondria from normal cells.
Thus, these cell-level results establish the connection
between Ab oligomers and BAK-dependent apoptotic
pathway. Our in vitro single-vesicle study goes much further
by uncovering the underlying mechanisms by which Ab
oligomers induce cytochrome c release and identify that
Ab oligomers’ sole interaction with BAK is sufficient to
induce apoptotic BAK pores. Using a cofloatation assay,
we show that Ab oligomers bind directly with BAK on the
membrane, providing the molecular basis for its role in
the cytochrome c-dependent apoptotic pathway.
Recently, however, Camilleri et al. (17) argued that the
disruption of lipid membrane integrity may be the reason
for the Ab oligomer toxicity on isolated mitochondria. We
note that much higher concentrations of Ab oligomers
were used in their in vitro study than in ours, which could
have made the vesicles leaky for small contents in their
long observation time. In sharp contrast, we did not observe
the release of much larger cytochrome c in our single-vesicle
assay. Furthermore, significantly reduced cytochrome c
release levels was observed in isolated mitochondria from
BAK KD HT-22 cells, which clearly substantiates the role
of BAK in Ab oligomers-induced cytochrome c release.
Interestingly, we also observed vesicle populations with
multiple steps in our in vitro single-vesicle assay (seeFIGURE 5 A proposed model of Ab oligomer function on apoptotic
BAK pore formation. (A) Normal apoptotic pathway; tBID induces confor-
mational change of BAK, inducing membrane insertion followed by oligo-
merization, which results in apoptotic BAK pores. (B) Ab oligomers hijack
the apoptotic pathway by inducing BAK conformational change such that
apoptotic BAK pores are formed in the absence of the death signal. To
see this figure in color, go online.Fig. S5). Had abrupt membrane rupture been the cause
of cytochrome c release, we would have observed only
single-step time traces. Further, experiments employing
SRB-dextran displayed content release for a fivefold-higher
number of vesicles than when we used Cy3-labeled cyto-
chrome c, indicating that some openings in the membrane
are large enough to allow SRB-dextran but not sufficient
for cytochrome c. Thus, our results suggest that Ab oligo-
mers indeed induce apoptotic BAK pores.
Our results were possible because of our in vitro single-
vesicle cytochrome c release assay. Previous cell-based
assays that measure the amount of cytochrome c released
from the mitochondria (15,16,28) do not provide temporal
information and the closeup examination of the relevant
protein machinery is difficult. An ensemble, in vitro release
assay using small fluorescence probes could provide real-
time dynamics and identifications of relevant protein ma-
chinery, but are not able to discriminate physiological
apoptotic pores (22,30,41). In contrast, the significance of
our assay is that we can monitor the cytochrome c levels
within individual MOM-like vesicles and detect pores suffi-
cient for cytochrome c release. Our assay should be gener-
ally applicable to the studies of other pro/anti-apoptotic
proteins and other protein translocation pores.
Although we show that Ab oligomers are sufficient to
induce apoptotic BAK pores in a minimalistic setting, we
cannot completely exclude the possibility of Ab oligomers
interacting with other apoptotic bcl-2 family proteins such
as BAX (10–12,33,42) or hindering BAK-inhibiting pro-
teins such as VDAC2 (43,44). Also, our BAK KD ex-
periments were conducted using HT-22 cells from the
hippocampal neuronal cell line. Because neuronal cell death
is common within the cerebral cortex (8,45), further exper-
iments using primary cultured cortical neurons is warranted.
In conclusion, we show that even in the absence of normal
apoptotic signals such as tBID, Ab oligomers can directly
interact with BAK and release cytochrome c. Thus, our re-
sults suggest that even without a death signal, the presence
of Ab oligomers alone can trigger neuronal cell death, which
is in coherence with the progression of AD. Our results also
suggest that Ab oligomers have the capacity to amplify the
death signal, which could transform a normally tolerable
apoptotic signal to a faithful on-signal for cell death.SUPPORTING MATERIAL
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